🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH

Ellen Gravallese update on RA pathogenesis Her take on RA interception studies “While drug repurposing has not proven capable of preventing transition from Pre RA to RA, we need to better understand disease mechanisms to offer other interventions” @RheumNow #APLAR25 @APLAR_org https://t.co/d39ihVvWyA

One of the most impt updates recommended to add a bDMARD if tx target is not achieved by the 1st csDMARD (no more prognostic stratification) But, accdg to Dr. Smolen, adding a 2nd csDMARD should still be considered especially in resource-limited countries. @RheumNow #APLAR25 https://t.co/ZQiviGcrYp

Dr. Josef Smolen discusses 2025 EULAR updates for RA. He highlighted the importance of OP A - that tx should be a shared decision making between px and rheuma in order to ensure better care and disease control. @RheumNow #aplar25 #APLAR25 https://t.co/KOJbiK87TS

Methotrexate significantly lowers Systolic BP Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs. https://t.co/HDnDWahuul

SSc-ILD ABs & LESSONS: 30% of won't progress. Triple negatives (ATA, ACA, ARA) wont progress. Males & diffuse dz > predictive than Abs. Great read on if Abs are biomarkers to predict Rx effect. https://t.co/YcZt4aAvL0 https://t.co/wOknKRfRHf

ACR Concerns on the Scientific Integrity at the CDC On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to https://t.co/P2J7eZN07W

Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective(OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://t.co/DbsJVZ16Zd

Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/DPgDQsCWK9

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/sSzMvDUMf5

Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/QLod6uj2Dj

Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/8IWXWZmWgE